GlassScriptPhysician profile
Torri J Pierce
NPI 1558555979
$3,173.15
in general payments reported to CMS, 2019-2025
35 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $430 · 2021: $182 · 2022: $592 · 2023: $694 · 2024: $524 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $594.46 | 2019-2024 | Slynd |
| Abbvie INC. | $448.35 | 2019-2022 | |
| Gynesonics, INC. | $156.29 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $148.57 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $138.51 | 2022-2025 | |
| Therapeuticsmd, INC. | $124.43 | 2019-2022 | |
| Medical Device Business Services, INC. | $121.83 | 2019 | |
| Astellas Pharma US INC | $119.85 | 2023-2024 | Veozah |
| Acessa Health INC. | $119.72 | 2022 | |
| Ethicon US, LLC | $92.41 | 2019-2024 | Stratafix, Ethicon, Evarrest |
| Avion Pharmaceuticals | $88.32 | 2020-2023 | Balcoltra |
| Applied Medical Resources Corporation | $80.22 | 2022-2023 | Gelpoint V-Path |
| Caldera Medical, INC | $79.78 | 2023 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $71.44 | 2019-2023 | |
| Myovant Sciences INC. | $70.98 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $67.30 | 2020-2025 | Femring, Intrarosa, Femlyv |
| Merck Sharp & Dohme LLC | $65.65 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $65.14 | 2023 | Myfembree |
| Pfizer INC. | $64.79 | 2019-2025 | |
| Dexcom, INC. | $49.62 | 2024-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $47.47 | 2020-2023 | Thinprep 2000 Processor, Aptima |
| Currax Pharmaceuticals LLC | $45.96 | 2023 | Contrave, Onzetra Xsail |
| Sage Therapeutics, LLC | $39.77 | 2024-2025 | Zurzuvae |
| Mission Pharmacal Company | $34.84 | 2019-2023 | Citranatal |
| Meditrina | $34.58 | 2020-2023 | |
| Shield Therapeutics INC | $31.35 | 2022-2023 | Accrufer |
| Exact Sciences Corporation | $23.86 | 2024 | Cologuard Collection Kit |
| Medicem INC. | $21.95 | 2020 | |
| Mylan Pharmaceuticals INC. | $21.24 | 2022 | |
| Allergan, INC. | $20.48 | 2020 | |
| Organon LLC | $19.98 | 2023-2024 | Jada System |
| Duchesnay USA Incorporated | $18.40 | 2019 | |
| Evofem Biosciences, INC. | $16.74 | 2025 | Solosec, Phexx, Phexxi |
| Supernus Pharmaceuticals, INC. | $14.88 | 2025 | Qelbree |
| Coopersurgical, INC. | $13.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Torri Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.